Coya Therapeutics, Inc. (COYA): Total Liabilities
$6.92M
As of 2025-12-31
$4.03M
As of 2026-06-30
-25.6%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.92M | +45.1% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $4.77M | -15.2% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $5.63M | -66.5% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $16.79M | n/m | 2024-03-19, Balance as of period end |
| 2021-12-31 | $1.15M | n/a | 2023-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $30.24M | -28.7% |
| Adagene Inc. (ADAG) | 2025-12-31 | $26.36M | -32.0% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $416.27M | +66.7% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $51.40M | +18.9% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $20.27M | -15.3% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $14.52M | -18.6% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $22.84M | -34.9% |
Compare COYA, ACRS, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗